Akshanth R Polepally

12PUBLICATIONS

28CO-AUTHORS

Predictive and prognostic markersMolecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Obstetrics and gynaecology

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (12)

Sort by Publication Date:

|May 10, 2026

Semi-Mechanistic PK/PD Modeling of Platelets and Spleen Volume With Navitoclax in Combination With Ruxolitinib in Patients With Myelofibrosis.

|Mar 27, 2025

Pharmacokinetics and Safety of Navitoclax in Hepatic Impairment.

Maulik Patel, Jalaja Potluri, Thomas Marbury

|Nov 30, 2023

Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study.

Carla Biesdorf, Xiaowen Guan, Satya R Siddani

|Aug 27, 2022

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.

Anita D'Souza, Nina Shah, Cesar Rodriguez

|Apr 06, 2021

First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors.

George D Demetri, Jason J Luke, Antoine Hollebecque

|Oct 12, 2020

Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist.

Akshanth R Polepally, Juki W Ng, Ahmed Hamed Salem

Pageof 2

Frequent Collaborators

Insa Winzenborg

Ahmed Nader

Mohamad Shebley

Juki W Ng

Rajeev M Menon

Carla Biesdorf

Ahmed A Othman

Cheri E Klein

Benjamin Engelhardt

Peter Noertersheuser

Frequent Collaborators

Insa Winzenborg

Ahmed Nader

Mohamad Shebley

Juki W Ng